Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESOLVE: AP1189 in rheumatoid arthritis patients with inadequate response to methotrexate
2022-002605-26Phase 2Completed
- Sponsor
- SynAct Pharma AB
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing AP1189 arm with Placebo arm (2 arms). Primary endpoint: Primary Safety Endpoint. Started Oct 2022; status: completed.
02
Drugs
resomelagon
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2022-002605-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002605-26.